可解释的人工智能框架,用于预测与年龄相关的黄斑退化症治疗结果
Mini Han Wang1,2,3
1Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China.
Sensors (Basel, Switzerland)
|November 27, 2025
概括
这项研究引入了一种新的混合人工智能框架,将大型语言模型和神经符号推理结合起来,以解释与年龄相关的黄斑变性 (AMD) 治疗预后. 该模型使用多模式数据准确预测患者的结果,提供透明,基于证据的风险评估.
科学领域:
- 眼科医生 眼科 眼科
- 人工智能的人工智能
- 医疗信息学 医疗信息学
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是不可逆转的视力丧失的主要原因.
- 目前用于预测AMD治疗结果的方法缺乏透明度和灵活性.
- 在AMD管理中需要先进的决策支持系统.
研究的目的:
- 开发和验证一个混合的神经符号和大语言模型 (LLM) 框架,以解释AMD治疗预后.
- 将机械性疾病知识与多式眼科数据相结合,以提高预测准确度.
- 为个性化的AMD治疗规划提供透明,基于证据的风险分层.
主要方法:
- 研究了一组10名经过手术治疗的AMD患者的试点队列.
- 包括临床文件和眼科成像 (OCT,FA,SLO,B-scan US) 在内的多模式数据被收集和处理.
- 一种神经符号的方法结合了特定领域的眼科知识图表与精细调整的眼科文献和电子健康记录的LLM.
主要成果:
- 混合型号在独立测试集 (AUROC 0.94,AUPRC 0.92,Brier 分数 0.07) 上取得了高性能,表现优于基线模型.
- 可解释性指标表明,超过85%的预测得到了知识图规则的支持,超过90%的叙述引用了关键生物标志物.
- 一个案例研究显示了治疗需求和潜在并发症的准确实时风险分层.
结论:
- 拟议的框架有效地整合了多式联络证据,以获得可解释的AMD治疗预后.
- 这种方法提供了透明的因果推理,并支持个性化治疗规划.
- 该研究建立了一个可扩展的,隐私意识的模板,用于在AMD和其他视网膜疾病中提供下一代决策支持.
更多相关视频
09:24A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
Published on: March 10, 2023
2.3K
06:16Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
3.0K
相关概念视频
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
